{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:18:10Z","timestamp":1770967090102,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.clml.2013.11.001","type":"journal-article","created":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T13:01:16Z","timestamp":1384434076000},"page":"223-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed\/Refractory Leukemia or Myelofibrosis"],"prefix":"10.1016","volume":"14","author":[{"given":"James","family":"Foran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray","family":"Yule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Langford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Ayrton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Lock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautham","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2013.11.001_bib1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrm1245","article-title":"The cellular geography of Aurora Kinases","volume":"4","author":"Carmena","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.clml.2013.11.001_bib2","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1038\/sj.onc.1201065","article-title":"A\u00a0putative serine\/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines","volume":"14","author":"Sen","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2013.11.001_bib3","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1093\/emboj\/17.11.3052","article-title":"A\u00a0homologue of Drosophila aurora kinase\u00a0is\u00a0oncogenic and amplified in human colorectal cancers","volume":"17","author":"Bischoff","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/j.clml.2013.11.001_bib4","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/jnci\/91.13.1160","article-title":"Mitotic kinase expression and colorectal cancer progression","volume":"91","author":"Katayama","year":"1999","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2013.11.001_bib5","first-page":"593","article-title":"Amplification\/overexpression of Aurora-A in human gastric carcinoma: potential role in differentiated type gastric carcinogenesis","volume":"12","author":"Kamada","year":"2004","journal-title":"Oncol Rep"},{"key":"10.1016\/j.clml.2013.11.001_bib6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2011.08898.x","article-title":"The potential role of Aurora kinase inhibitors in haematological malignancies","volume":"155","author":"Farag","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.11.001_bib7","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/leu.2010.15","article-title":"Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias","volume":"24","author":"Moore","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.11.001_bib8","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/leu.2012.256","article-title":"Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target","volume":"27","author":"Hartsink-Segers","year":"2013","journal-title":"Leukaemia"},{"key":"10.1016\/j.clml.2013.11.001_bib9","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1182\/blood-2011-07-366930","article-title":"Phase 1\/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia","volume":"118","author":"L\u00f6wenberg","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.11.001_bib10","doi-asserted-by":"crossref","first-page":"11011","DOI":"10.1073\/pnas.0504952102","article-title":"Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases","volume":"102","author":"Carter","year":"2005","journal-title":"PNAS"},{"key":"10.1016\/j.clml.2013.11.001_bib11","unstructured":"Goodall J, Squires MS, Lock V, et\u00a0al. AT9283, a multi-targeted kinase inhibitor, has potent activity in AML cell lines and patient samples. Poster 1613, American Society of Hematology (ASH) annual meeting,\u00a02008."},{"key":"10.1016\/j.clml.2013.11.001_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059791","article-title":"JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis","author":"Barosi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2013.11.001_bib13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/2040620712437754","article-title":"Myelofibrosis 2012: it's complicated","volume":"3","author":"Hubbeling","year":"2012","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2013.11.001_bib14","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/1078-0432.CCR-12-0284","article-title":"Molecular pathways: Jak\/STAT pathway: mutations, inhibitors, and resistance","volume":"19","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.11.001_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030734","article-title":"Evolution of resistance to Aurora kinase B inhibitors in leukaemia cells","author":"Failes","year":"2012","journal-title":"PLoS One"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013004588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013004588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:20Z","timestamp":1761870320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265013004588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S2152265013004588"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2013.11.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed\/Refractory Leukemia or Myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2013.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}